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Recent comprehensive molecular profiling in many types of cancers has revealed oncogenic mutations and the aberrant expressions of protein‐coding genes. However, because the coding genome accounts for \<2% of all DNA sequences and many mutations were reported in non‐coding sequences,[1](#cas13342-bib-0001){ref-type="ref"} the dysregulation of non‐coding RNAs might affect tumor phenotypes. For example, significant numbers of non‐coding RNAs such as microRNA (miRNA, miR), siRNA, piwi‐interacting RNA, and long non‐coding RNAs (lncRNAs), were recently discovered and identified as biologically functional non‐coding RNAs, some of which had a significant impact on tumor biology.[2](#cas13342-bib-0002){ref-type="ref"}

Among such non‐coding RNAs, miRNAs are short non‐coding RNAs (approximately 22 nt long) that bind to short regions of complementary sequences of target mRNAs to post‐transcriptionally regulate the expression of target genes. MicroRNAs have important roles in a wide variety of pathological processes related to tumor formation. The aberrant expression of miRNA was shown to induce tumor suppression or induce oncogenic effects resulting in tumor formation.[2](#cas13342-bib-0002){ref-type="ref"} Extensively studied examples of tumor‐suppressive miRNAs include the let‐7, miR‐15a/16‐1, miR‐26a, or miR‐34 family members, which are associated with antiproliferative, antitumorigenic, and pro‐apoptotic activities and whose expressions are sometimes aberrantly suppressed in many types of cancers. Examples of oncogenic miRNAs include the miR‐17‐92 cluster, miR‐155, and miR‐21, the functions of which are associated with the repression of tumor‐suppressor genes such as *PTEN* and *CDKN1A*, and whose expressions are sometimes aberrantly upregulated in cancers.[3](#cas13342-bib-0003){ref-type="ref"}

In addition to miRNAs, lncRNAs, defined as transcripts \>200 nt in length, are also functional. Although the precise roles of the vast majority of \~40 000 lncRNAs are still under investigation,[4](#cas13342-bib-0004){ref-type="ref"} some of these transcripts were shown to be potential key regulators of cellular differentiation and proliferation, as well as having oncogenic functions in many types of cancers.[5](#cas13342-bib-0005){ref-type="ref"}, [6](#cas13342-bib-0006){ref-type="ref"} Furthermore, studies have shown that lncRNAs affect chromatin structure and RNA interactions, such as the miRNA sponge, which upregulates protein expression by inhibiting the binding of miRNAs to their targets.[6](#cas13342-bib-0006){ref-type="ref"}, [7](#cas13342-bib-0007){ref-type="ref"}

With regard to RNA interactions between lncRNAs and miRNA in cancers, Hox transcript antisense intergenic RNA (HOTAIR), an lncRNA, has an oncogenic role in tumor formation by upregulating fibroblast growth factor 1 by sponging miR‐326, which activates the PI3K/AKT and MEK1/2 pathways.[8](#cas13342-bib-0008){ref-type="ref"} We also recently found that Notch1 activation in glioma cells specifically induced the expression of lncRNA for taurine upregulated gene 1 (TUG1), which coordinately promoted self‐renewal by sponging miR‐145.[9](#cas13342-bib-0009){ref-type="ref"}

Thus, accumulating studies of cancer‐associated lncRNAs have reported their roles in the multiple pathological steps of tumorigenesis, including cell proliferation, cellular signaling, angiogenesis, and metastasis, which may provide a strong rationale for the targeting of lncRNAs as a specific and potent therapeutic approach to eliminate cancer cells.[6](#cas13342-bib-0006){ref-type="ref"} In this review, we provide a summary of the current understanding of lncRNAs, including TUG1, which were recently reported to have pathological roles in cancer, and we discuss the future perspective of targeting lncRNAs as a new approach for cancer treatment.

Roles of lncRNA in gene regulation {#cas13342-sec-0002}
==================================

Recent studies reported the regulatory mechanisms of gene expression by lncRNAs in at least seven pathways (Fig. [1](#cas13342-fig-0001){ref-type="fig"}).[10](#cas13342-bib-0010){ref-type="ref"}, [11](#cas13342-bib-0011){ref-type="ref"}, [12](#cas13342-bib-0012){ref-type="ref"}, [13](#cas13342-bib-0013){ref-type="ref"} These functions are closely associated with the subcellular localization of lncRNAs, although the precise factors (e.g. binding proteins) and sequence elements in lncRNAs that determine their localization remain largely unknown.[14](#cas13342-bib-0014){ref-type="ref"} Generally, lncRNAs have a more nuclear‐biased localization pattern when compared with mRNAs, although large amounts of lncRNAs are located in the cytoplasm.[14](#cas13342-bib-0014){ref-type="ref"} This localization bias may support the idea that lncRNAs function as essential molecules in the scaffolding and recruitment of multiple proteins to specific genomic loci to form 3‐D nuclear structures, which affect gene expression (Fig. [1](#cas13342-fig-0001){ref-type="fig"}). Furthermore, nascent RNA transcripts in the nucleus are processed by different methods including splicing, polyadenylation, 5ʹ‐capping, and methylation. During these processes, lncRNAs affect RNA splicing and mRNA stability. For example, metastasis‐associated lung adenocarcinoma transcript 1 (MALAT1), which is restricted to the nucleus, especially to nuclear speckles, affects alternative splicing through interactions with serine/arginine‐rich splicing factors and pre‐mRNA.[13](#cas13342-bib-0013){ref-type="ref"}, [15](#cas13342-bib-0015){ref-type="ref"} In addition to their nuclear functions, cytoplasmic lncRNAs function as a modulator by interacting with other types of RNAs (e.g. competitive endogenous RNAs \[ceRNAs\]). These functions of lncRNAs are exemplified and explained in more detail below.

![Multiple long non‐coding RNA (lncRNA) mechanisms of gene regulation, which rely on interactions with multiple molecules. In the nucleus, lncRNAs regulate gene expression by controlling the local chromatin structure or recruiting regulatory molecules to specific loci. In the cytoplasm, lncRNAs interact with other types of RNA and affect functions including mRNA stability, mRNA translation, or microRNA (miRNA) sponge. CDS, coding sequence; circRNA, circular RNA; Pol II, RNA polymerase II.](CAS-108-1927-g001){#cas13342-fig-0001}

Interactions between chromatin regulatory proteins and lncRNAs {#cas13342-sec-0003}
--------------------------------------------------------------

Long non‐coding RNAs regulate gene expression through their scaffolding activity for chromatin modifying proteins (e.g. methyltransferases, demethylases, acetyltransferases, and deacetylases), and recruiting these proteins to target loci through cis‐regulation (regulation of the transcription of nearby genes) or trans‐regulation (regulation of the transcription of genomically distant genes). These interactions occur by affecting the nuclear structure.[16](#cas13342-bib-0016){ref-type="ref"}

One of the most studied lncRNAs is X‐inactive specific transcript (Xist), which is expressed from one of the two X chromosomes at the initial phase of X chromosome inactivation (XCI) in early female embryonic development. Xist binds to chromatin by scaffold attachment factor A (also known as hnRNPU) and recruits SMRT/histone deacetylase 1 (HDAC1)‐associated repressor protein (SHARP), which interacts with HDAC3, polycomb repressive complex 1 (PRC1), and PRC2.[17](#cas13342-bib-0017){ref-type="ref"}, [18](#cas13342-bib-0018){ref-type="ref"} Intriguingly, although the induction of Xist expression and the recruitment of SHARP‐HDAC3 are prerequisites for the initiation of XCI, Xist appears to be dispensable for the maintenance of transcriptional inactivation.[16](#cas13342-bib-0016){ref-type="ref"}, [19](#cas13342-bib-0019){ref-type="ref"} Furthermore, it appears that the presence of PRC2 is not required for the initiation of XCI, because the genetic deletion of PRC2 had no effect on the initiation of transcriptional silencing,[20](#cas13342-bib-0020){ref-type="ref"}, [21](#cas13342-bib-0021){ref-type="ref"} although it was required for the maintenance of transcriptional inactivation.[22](#cas13342-bib-0022){ref-type="ref"}

Similar to Xist, a set of lncRNAs are thought to interact with PRC2, resulting in gene inactivation of certain specific genome loci. HOTAIR is transcribed in the Homeobox (HOX) C gene cluster region on chromosome 12 and is co‐expressed with the HOXC genes.[23](#cas13342-bib-0023){ref-type="ref"} HOTAIR regulates the expression of HOXD genes in chromosome 2 through transregulation, whereas interactions between HOTAIR, lysine‐specific demethylase 1, and PRC2 promotes coordinated H3K27 methylation and H3K4 demethylation. Many cancers, including breast cancer, pancreatic cancer, non‐small‐cell lung cancer (NSCLC), and gastrointestinal stromal tumor overexpress HOTAIR, which affects tumor behavior.[24](#cas13342-bib-0024){ref-type="ref"}, [25](#cas13342-bib-0025){ref-type="ref"}, [26](#cas13342-bib-0026){ref-type="ref"}, [27](#cas13342-bib-0027){ref-type="ref"} For example, the overexpression of HOTAIR in breast cancer cells increased their invasive and metastatic abilities and reprogramed PRC2 occupancy throughout the genome, which is similar to embryonic fibroblasts.[24](#cas13342-bib-0024){ref-type="ref"}

A recent study showed that although HOTAIR binds to PRC2 with a high affinity to silence target loci by H3K27me3 deposition, the genetic deletion of PRC2 components did not affect the silencing activity of HOTAIR, indicating that PRC2 is dispensable for the initiation of HOTAIR‐mediated silencing machinery.[28](#cas13342-bib-0028){ref-type="ref"} This is similar to Xist‐mediated gene silencing, as mentioned above. These two examples of functional interactions between an lncRNA (Xist and HOTAIR) and PRC2 suggest interesting mechanistic consequences of lncRNA‐guided gene regulation, in which many chromatin regulatory proteins are involved. Thus, in addition to the dysregulation of many chromatin modifiers such as histone modification enzymes and chromatin remodelers that have been comprehensively analyzed in many cancers, the dysregulation of lncRNAs may also play an important functional role in tumorigenesis.

Interactions between lncRNAs and other types of RNA {#cas13342-sec-0004}
---------------------------------------------------

Long non‐coding RNAs interact with other types of RNA molecules in cells, such as mRNA and miRNA, and modulate their stability, splicing, translation, and metabolism (Fig. [1](#cas13342-fig-0001){ref-type="fig"}). MALAT1, a highly abundant lncRNA, regulates alternative splicing through interactions with serine/arginine‐rich splicing factors and pre‐mRNA.[15](#cas13342-bib-0015){ref-type="ref"}, [29](#cas13342-bib-0029){ref-type="ref"} Details of MALAT1 functions were well documented in a recent review.[30](#cas13342-bib-0030){ref-type="ref"} In cancer studies, the high expression of MALAT1 in NSCLC was associated with metastatic progression.[31](#cas13342-bib-0031){ref-type="ref"} The genetic loss or systemic knockdown of Malat1 in a mouse cancer model resulted in slower tumor growth and a reduction in the metastasis of lung cancer and breast cancer.[32](#cas13342-bib-0032){ref-type="ref"}, [33](#cas13342-bib-0033){ref-type="ref"} Long non‐coding RNAs also stabilize mRNA. Terminal tissue differentiation‐inducing ncRNA (TINCR) is a characteristic lncRNA that binds to mRNAs with a 25‐nt TINCR box motif.[34](#cas13342-bib-0034){ref-type="ref"} TINCR recruits Staufen‐1 protein, a regulator of tissue differentiation, to mRNA with a TINCR box motif, and stabilizes the target mRNAs to promote its translation.

Recently, a model of ceRNA was proposed, where abundant cytoplasmic lncRNAs containing miRNA‐binding sites interacted with miRNAs through their seed sequences (i.e. sequence‐specific sequester) to reduce their regulatory effect on target mRNA, the so‐called miRNA sponge.[13](#cas13342-bib-0013){ref-type="ref"} Phosphatase and tensin homolog (*PTEN*) is a well‐known tumor‐suppressor gene. Studies have shown that PTEN pseudogene 1 (PTENP1) increased PTEN protein levels by competing for a set of PTEN‐targeting miRNAs, which downregulate PTEN independent of its protein‐coding function.[35](#cas13342-bib-0035){ref-type="ref"}, [36](#cas13342-bib-0036){ref-type="ref"} In colon cancer, the loss of focal copy number at the PTENP1 locus was associated with the downregulation of PTEN expression in colon cancer patients. A similar relationship was shown between the oncogene *KRAS* and its pseudogene *KRAS1P* in colon cancer.[35](#cas13342-bib-0035){ref-type="ref"}

These lncRNA contributions to tumorigenesis through mechanisms including ceRNA have generated substantial interest and have been reported in many cancers.[6](#cas13342-bib-0006){ref-type="ref"}, [37](#cas13342-bib-0037){ref-type="ref"} However, the ceRNA hypothesis should consider the physiological stoichiometry of miRNAs and ceRNAs in cells because the suppressive activity of ceRNAs might be closely associated with miRNA cellular abundance.[38](#cas13342-bib-0038){ref-type="ref"}, [39](#cas13342-bib-0039){ref-type="ref"} Generally, high amounts of miRNAs are unlikely to be susceptible to ceRNA competition.[40](#cas13342-bib-0040){ref-type="ref"} Therefore, a similar abundance of ceRNAs is thought to be required for efficient competition with target miRNAs.[41](#cas13342-bib-0041){ref-type="ref"} Although further studies are required to clarify more precisely the regulatory cross‐talk between transcripts, including mRNAs, miRNAs, and lncRNAs, the ceRNA mechanism might explain the complexity of the dysregulation of mRNA through its 3ʹ‐UTR in cancers.

Mechanisms of dysregulated lncRNA expression in cancer {#cas13342-sec-0005}
======================================================

Increasing evidence has shown that the dysregulation of lncRNAs is associated with cancer pathogenesis and that lncRNAs function as regulators of cancer‐related genes.[6](#cas13342-bib-0006){ref-type="ref"}, [42](#cas13342-bib-0042){ref-type="ref"} Several lines of evidence showed that aberrant signal transduction induces lncRNA dysregulation (Fig. [2](#cas13342-fig-0002){ref-type="fig"}). The Notch signaling pathway plays a dominant role in inhibiting neural stem cell differentiation through the activities of its downstream effectors, such as Hairy and enhancer of split 1/5.[43](#cas13342-bib-0043){ref-type="ref"} A recent study showed that Notch triggered oncogenic activity through lncRNA activation in leukemia (Fig. [2](#cas13342-fig-0002){ref-type="fig"}a). In human T‐cell acute lymphoblastic leukemia, a set of lncRNAs, including leukemia‐induced non‐coding activator RNA (LUNAR1), are directly controlled by the Notch1 signaling. LUNAR1 is required for T‐cell acute lymphoblastic leukemia growth through the enhancement of insulin‐like growth factor 1 receptor expression and sustained insulin‐like growth factor 1 signaling.[44](#cas13342-bib-0044){ref-type="ref"} Notch1 signaling also induces another lncRNA, TUG1,[9](#cas13342-bib-0009){ref-type="ref"} which is a cancer‐related lncRNA that binds to PRC2 or PRC1 and also represses gene expression in glioma cells.[45](#cas13342-bib-0045){ref-type="ref"}, [46](#cas13342-bib-0046){ref-type="ref"}

![Aberrant signal transduction induces long non‐coding RNA (lncRNA) dysregulation in cancer cells. (a) Notch triggers oncogenic activity by the activation of two different lncRNAs (leukemia‐induced non‐coding activator RNA \[LUNAR1\] and taurine upregulated gene 1 \[TUG1\]) in cancers. LUNAR1 enhances insulin‐like growth factor 1 receptor (IGF1R) expression through a *cis*‐activation mechanism in leukemia (left). TUG1 coordinately promotes self‐renewal by sponging microRNA‐145 (miR‐145) in the cytoplasm and recruiting polycomb repressive complex 2 (PRC2) to repress differentiation genes by the locus‐specific methylation of histone H3K27 by YY1 binding activity in glioma stem cells. Me, methylation; Pol II, RNA polymerase II. (b) LncRNA activated by transforming growth factor‐β (TGF‐β) (lncRNA‐ATB) is upregulated by TGF‐β signaling in hepatocellular carcinoma. LncRNA‐ATB upregulates Zinc finger E‐box‐binding homeobox (ZEB)1 and ZEB2 by sequestering miR‐200 family members (miR‐200s) and inducing epithelial mesenchymal transition and invasion. In addition, lncRNA‐ATB promotes the organ colonization of tumor cells by binding to interleukin (IL)‐11 mRNA.](CAS-108-1927-g002){#cas13342-fig-0002}

Long non‐coding RNA activated by TGF‐β (lncRNA‐ATB) was upregulated by transforming growth factor‐β signaling in hepatocellular carcinoma metastases. This lncRNA upregulates Zinc finger E‐box‐binding homeobox 1 and 2 by competitively binding to miR‐200 family members to induce epithelial--mesenchymal transition and invasion. Furthermore, lncRNA‐ATB promoted the organ colonization of tumor cells by binding to interleukin‐11 mRNA and triggering signal transducer and activator of transcription 3 signaling (Fig. [2](#cas13342-fig-0002){ref-type="fig"}b).[10](#cas13342-bib-0010){ref-type="ref"}

These studies indicate that a set of lncRNAs may act as key regulators of signaling pathways. Downstream of the cancer‐promoting signals, lncRNAs may sustain cancer cell proliferation and enhance viability and motility, which are linked to the clinically relevant cancer subtypes that predict tumor behavior and prognosis.

Taurine upregulated gene 1 plays important roles in tumorigenesis {#cas13342-sec-0006}
=================================================================

We recently identified the Notch‐regulated lncRNA, TUG1, in glioma cells by whole‐genome RNA sequencing and comprehensively characterized its function in relation to gliomagenesis.[9](#cas13342-bib-0009){ref-type="ref"} Taurine upregulated gene 1 is a cancer‐related lncRNA that binds to PRC2 or PRC1.[45](#cas13342-bib-0045){ref-type="ref"}, [46](#cas13342-bib-0046){ref-type="ref"} This lncRNA was originally identified as a transcript upregulated by taurine, whose function is associated with retinal development.[47](#cas13342-bib-0047){ref-type="ref"} It is overexpressed in bladder cancer, gastric cancer, and osteosarcoma;[48](#cas13342-bib-0048){ref-type="ref"}, [49](#cas13342-bib-0049){ref-type="ref"}, [50](#cas13342-bib-0050){ref-type="ref"} in contrast, it is downregulated in NSCLC,[51](#cas13342-bib-0051){ref-type="ref"} suggesting context‐dependent roles in different types of cancers (Table [1](#cas13342-tbl-0001){ref-type="table-wrap"}). Because the length of TUG1 lncRNA is long (approximately 7.1 kb), it is plausible that TUG1 has multiple functions.

###### 

Function of taurine upregulated gene 1 (TUG1) in human cancers

  Cancer type                                                                                                                                     Molecular function
  ----------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------
  Oncogenic function                                                                                                                              
  Glioma[53](#cas13342-bib-0053){ref-type="ref"}                                                                                                  miRNA sponge (miR‐144)
  Glioma[9](#cas13342-bib-0009){ref-type="ref"}                                                                                                   Recruitment of PRC2, miRNA sponge (miR‐145)
  Glioma[54](#cas13342-bib-0054){ref-type="ref"}                                                                                                  miRNA sponge (miR‐26a)
  Glioma[55](#cas13342-bib-0055){ref-type="ref"}                                                                                                  miRNA sponge (miR‐299)
  Oral squamous cell carcinoma[56](#cas13342-bib-0056){ref-type="ref"}                                                                            Unknown
  Esophageal squamous cell carcinoma[57](#cas13342-bib-0057){ref-type="ref"}, [58](#cas13342-bib-0058){ref-type="ref"}                            Unknown
  Cervical cancer[59](#cas13342-bib-0059){ref-type="ref"}                                                                                         Unknown
  Small cell lung cancer[60](#cas13342-bib-0060){ref-type="ref"}                                                                                  Recruitment of PRC2
  Gastric cancer[61](#cas13342-bib-0061){ref-type="ref"}                                                                                          miRNA sponge (miR‐144)
  Gastric cancer[62](#cas13342-bib-0062){ref-type="ref"}                                                                                          Recruitment of PRC2
  Hepatocellular carcinoma[63](#cas13342-bib-0063){ref-type="ref"}                                                                                Recruitment of PRC2
  Hepatoblastoma[64](#cas13342-bib-0064){ref-type="ref"}                                                                                          miRNA sponge (miR‐34a)
  Gallbladder carcinoma[65](#cas13342-bib-0065){ref-type="ref"}                                                                                   miRNA sponge (miR‐300)
  Breast cancer[66](#cas13342-bib-0066){ref-type="ref"}                                                                                           miRNA sponge (miR‐9)
  Breast cancer[67](#cas13342-bib-0067){ref-type="ref"}                                                                                           Unknown
  Colorectal cancer[68](#cas13342-bib-0068){ref-type="ref"}, [69](#cas13342-bib-0069){ref-type="ref"}, [70](#cas13342-bib-0070){ref-type="ref"}   Unknown
  Ovarian cancer[71](#cas13342-bib-0071){ref-type="ref"}                                                                                          Unknown
  Renal cell carcinoma[72](#cas13342-bib-0072){ref-type="ref"}                                                                                    Unknown
  Bladder cancer[49](#cas13342-bib-0049){ref-type="ref"}                                                                                          Unknown
  Bladder cancer[48](#cas13342-bib-0048){ref-type="ref"}                                                                                          miRNA sponge (miR‐145)
  Bladder cancer[73](#cas13342-bib-0073){ref-type="ref"}                                                                                          Unknown
  Osteosarcoma[50](#cas13342-bib-0050){ref-type="ref"}                                                                                            Unknown
  Osteosarcoma[74](#cas13342-bib-0074){ref-type="ref"}                                                                                            miRNA sponge (miR‐9)
  Osteosarcoma[75](#cas13342-bib-0075){ref-type="ref"}                                                                                            miRNA sponge (miR‐335)
  Tumor‐suppressive function                                                                                                                      
  Cervical cancer[46](#cas13342-bib-0046){ref-type="ref"}                                                                                         Recruitment of PRC1 and PRC2
  Non‐small‐cell lung carcinoma[51](#cas13342-bib-0051){ref-type="ref"}, [76](#cas13342-bib-0076){ref-type="ref"}                                 Recruitment of PRC2
  Prostate cancer[77](#cas13342-bib-0077){ref-type="ref"}                                                                                         miRNA sponge (unknown)

Text in parentheses shows target microRNA (miRNA, miR) of TUG1 in each cancer type. PRC, polycomb repressive complex.
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Expression of TUG1 is regulated by the Notch signaling pathway, and TUG1 was highly expressed in glioma stem cell populations and downregulated during its differentiation. Intriguingly, in cell nuclei, TUG1 physically interacts with PRC2, which might direct it to modify histone H3K27me3 levels in neuronal differentiation‐associated genes. In the cytoplasm, TUG1 shares miR‐145‐response elements with the mRNAs of several stemness markers (MYC and SOX2) and prevents them from miR‐145‐mediated degradation (Fig. [2](#cas13342-fig-0002){ref-type="fig"}). Importantly, the inhibition of TUG1 expression impaired stemness and tumorigenesis in gliomas both *in vitro* and *in vivo*, indicating that targeting TUG1 is a potent therapeutic approach to eliminate glioma stem cell populations.[9](#cas13342-bib-0009){ref-type="ref"} Indeed, antisense oligonucleotide (ASO) targeting TUG1, especially coupled with a potent drug delivery system, is an effective novel strategy for glioblastoma (GBM) treatment[9](#cas13342-bib-0009){ref-type="ref"} (Fig. [3](#cas13342-fig-0003){ref-type="fig"}). Cyclic Arg‐Gly‐Asp (cRGD) peptides are promising ligand molecules for targeting αvβ3 and αvβ5 integrins, which are frequently overexpressed in GBM cells. We used cRGD ligand‐conjugated polymeric micelles for delivery. These targetable polymeric micelles retained ASO accumulation within tumors. Although further investigations are required, cRGD‐mediated drug delivery is a powerful strategy for targeting GBMs through facilitated ASO delivery beyond the blood--brain tumor barrier.[52](#cas13342-bib-0052){ref-type="ref"}

![Inhibition of taurine upregulated gene 1 (TUG1) by an antiTUG1 drug delivery system (DDS) in a mouse xenograft model. Mice bearing brain tumors were given i.v. antisense oligonucleotide (ASO) targeting TUG1 coupled with a potent DDS using cyclic Arg‐Gly‐Asp peptide‐conjugated polymeric micelle (antiTUG1‐DDS). AntiTUG1‐DDS was specifically accumulated and retained in the tumors and markedly reduced tumor growth.[9](#cas13342-bib-0009){ref-type="ref"} Tumor areas are surrounded by red dotted line.](CAS-108-1927-g003){#cas13342-fig-0003}

Similar to miR‐145, TUG1 interacts with other miRNAs such as miR‐144, miR‐26a, miR‐299, miR‐34a, miR‐300, miR‐9, and miR‐335, in different types of cancers (Table [1](#cas13342-tbl-0001){ref-type="table-wrap"}). Although further experimental validation is required to clarify the impact of ceRNA mechanisms on tumorigenesis, TUG1 functions through a ceRNA mechanism that can dynamically change the transcriptome. Therefore, it will be particularly interesting to understand the pathologies of plastic cancer cells.

Concluding remarks {#cas13342-sec-0007}
==================

In this review, we exemplified and explained the functional roles of lncRNAs (Table [2](#cas13342-tbl-0002){ref-type="table-wrap"}) and discussed the future clinical implications of lncRNAs in cancers. Recent comprehensive studies have shown that, in addition to genetic alterations, the spatial and temporal epigenetic regulation of gene functions in pre‐cancer and cancer cells is particularly important in tumorigenesis. In particular, given that cancer cells are dynamic in response to extracellular signals, the plastic epigenetic control of gene expression plays a central role in cancer cell adaptation to new microenvironments. A better understanding of lncRNA pathways and other epigenetic mechanisms in cancer cells will hopefully provide multiple novel therapeutic strategies for devastating cancers in the near future.

###### 

Summary of key functions of the exemplified long non‐coding RNAs (lncRNA)

  LncRNA       Biological roles                            Molecular functions
  ------------ ------------------------------------------- -------------------------------------
  HOTAIR       Promotion of cell invasion and metastasis   Recruitment of PRC2, miRNA sponge
  TUG1         Promotion of cell proliferation             Recruitment of PRC2, miRNA sponge
  MALAT1       Regulation of alternative splicing          Splicing
  XIST         Inactivation of X chromosome                Recruitment of PRC2
  TINCR        Regulation of epidermal differentiation     Stabilization of mRNA
  PTENP1       Inhibition of cell proliferation            miRNA sponge
  KRAS1P       Promotion of cell proliferation             miRNA sponge
  LUNAR1       Promotion of cell proliferation             Chromosome looping
  lncRNA‐ATB   Promotion of cell invasion and metastasis   Stabilization of mRNA, miRNA sponge

HOTAIR, Hox transcript antisense intergenic RNA; lncRNA‐ATB, lncRNA activated by transforming growth factor‐β; LUNAR1, leukemia‐induced non‐coding activator RNA; MALAT1, metastasis‐associated lung adenocarcinoma transcript 1; miRNA, microRNA; PRC2, polycomb repressive complex 2; PTENP1, phosphatase and tensin homolog pseudogene 1; TINCR, tissue differentiation‐inducing ncRNA; TUG1, taurine upregulated gene 1; XIST, X‐inactive specific transcript.
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